CN111202735A - Application of chelerythrine in inhibiting growth of streptococcus pneumoniae - Google Patents
Application of chelerythrine in inhibiting growth of streptococcus pneumoniae Download PDFInfo
- Publication number
- CN111202735A CN111202735A CN202010139842.0A CN202010139842A CN111202735A CN 111202735 A CN111202735 A CN 111202735A CN 202010139842 A CN202010139842 A CN 202010139842A CN 111202735 A CN111202735 A CN 111202735A
- Authority
- CN
- China
- Prior art keywords
- streptococcus pneumoniae
- chelerythrine
- use according
- erythromycin
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims abstract description 63
- 229940031000 streptococcus pneumoniae Drugs 0.000 title claims abstract description 63
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 17
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 7
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 3
- 238000000338 in vitro Methods 0.000 claims abstract 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 13
- 229960003276 erythromycin Drugs 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 239000004098 Tetracycline Substances 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 7
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 7
- 229960002180 tetracycline Drugs 0.000 claims description 7
- 229930101283 tetracycline Natural products 0.000 claims description 7
- 235000019364 tetracycline Nutrition 0.000 claims description 7
- 150000003522 tetracyclines Chemical class 0.000 claims description 7
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010059866 Drug resistance Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960003376 levofloxacin Drugs 0.000 description 2
- 229960003702 moxifloxacin Drugs 0.000 description 2
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001017738 Chelidonium <beetle> Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000207919 Hydrophyllum Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 240000007849 Macleaya cordata Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010062545 Middle ear effusion Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 235000016319 Paullinia asiatica Nutrition 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010058859 Pneumococcal bacteraemia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 1
- 244000093732 Toddalia asiatica Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229930015421 benzophenanthridine alkaloid Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 208000024035 chronic otitis media Diseases 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 208000005923 otitis media with effusion Diseases 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of chelerythrine in inhibiting growth of streptococcus pneumoniae, which can inhibit growth of streptococcus pneumoniae by having a better in-vitro bactericidal effect on the streptococcus pneumoniae, wherein the minimum bactericidal concentration is 31.2 mu g/mL, and the minimum bacteriostatic concentration is 15.6 mu g/mL.
Description
Technical Field
The invention relates to the field of medicine and food safety, in particular to application of chelerythrine in inhibiting growth of streptococcus pneumoniae.
Background
Streptococcus pneumoniae (Streptococcus pneumoniae) is a gram-positive bacterium of the genus Streptococcus of the family Streptococcus, and causes various infections. Gram-negative results are obtained when the bacterial cells are senescent or after the bacteria are lysed by the production of autolytic enzymes. Streptococcus pneumoniae can also invade other parts of the body, causing middle ear effusion, chronic otitis media, transient deafness or speech retardation and the like, and even causing complications such as meningitis, endocarditis, shock and the like in severe cases. The pathogenic substances include capsule, streptococcus pneumoniae lysin O, lipoteichoic acid, neuraminidase and the like. 75% of adult pneumococcal pneumonia and more than 50% of severe pneumococcal bacteremia are caused by streptococcus pneumoniae types 1-8. Streptococcus pneumoniae types 6, 14, 19 and 23 often cause Streptococcus pneumoniae disease in children. It has been reported that each year, streptococcus pneumoniae infection causes 10 to 13.5 million people to be hospitalized with pneumonia, and more than 100 million children worldwide die each year from streptococcus pneumoniae infection.
Statistics show that the drug resistance rate of the streptococcus pneumoniae separated in 1997-2000 to penicillin is 8.8% -22.5%, and the drug resistance rate of the streptococcus pneumoniae to erythromycin is 42.5% -76.8%. 192 clinical isolated streptococcus pneumoniae which is detected by researchers such as Zhao iron plum and the like in China in 2003 has the drug resistance rate of 42.7 percent to penicillin and 77.6 percent to erythromycin. The drug resistance of streptococcus pneumoniae is increasing day by day, which has great influence on the treatment work of hospitals.
Chelerythrine (CHE), also called chelerythrine and chelerythrine quaternary ammonium base, is an isobomyl benzophenanthridine alkaloid separated from plants such as toddalia asiatica, chelidonium, macleaya cordata and sanguinea hydrophyllum, and has pharmacological activities such as antibiosis, anti-inflammation and the like and remarkable antitumor activity. The chelerythrine has inhibitory effect on certain fungi, bacteria and viruses, and can inhibit catarrh, Neisseria catarrhalis and Haemophilus influenzae. However, no literature report on the aspect of inhibiting the growth of the highly pathogenic streptococcus pneumoniae by chelerythrine is available at present.
Disclosure of Invention
The invention aims to solve the problem of drug resistance in clinical medicine and food safety at present and aims to provide the application of chelerythrine in inhibiting the growth of streptococcus pneumoniae.
In order to achieve the purpose, the invention adopts the technical scheme that:
the drug resistance of the streptococcus pneumoniae to antibiotics is determined by a micro-double dilution method, and then the Minimum Inhibitory Concentration (MIC) and the Minimum Bactericidal Concentration (MBC) of chelerythrine to the streptococcus pneumoniae are determined. The results show that: chelerythrine has good antibacterial effect on Streptococcus pneumoniae, and can be used for inhibiting growth of Streptococcus pneumoniae.
Preferably, the streptococcus pneumoniae is human streptococcus pneumoniae resistant to various antibiotics in erythromycin, tetracycline and sulfamethoxazole.
Preferably, the streptococcus pneumoniae is selected from human streptococcus pneumoniae resistant to erythromycin, tetracycline and sulfamethoxazole.
Preferably, the minimum bactericidal concentration of the chelerythrine is 31.2 mug/mL, and the minimum inhibitory concentration is 15.6 mug/mL.
The invention has the beneficial effects that:
the invention starts from the existing medicinal plant resource library, develops a potential drug-resistant bacteria inhibitor, finds that the non-antibiotic compound chelerythrine can effectively inhibit the growth of streptococcus pneumoniae based on the research on the action of chelerythrine on streptococcus pneumoniae, provides a new thought and source for the research, development and application of the streptococcus pneumoniae inhibitor, and has wide application value in the fields of medicine and the like.
Furthermore, the invention defines the inhibition effect of chelerythrine on streptococcus pneumoniae, and the chelerythrine serving as an antibiotic substitute can effectively relieve or solve the problems of drug resistance and infection of streptococcus pneumoniae and reduce the fatality rate.
Detailed Description
The present invention will be described in further detail with reference to examples. The examples are only for explaining the present invention and do not limit the scope of protection of the present invention.
1. Drug sensitivity test of streptococcus pneumoniae
The invention takes a plurality of humanized streptococcus pneumoniae (strain samples are taken from Haizi hospital in Beijing) as starting strains, and selects 10 common antibiotics such as levofloxacin, ofloxacin, moxifloxacin, erythromycin, chloramphenicol, telithromycin, tetracycline, vancomycin, linezolid and compound sulfamethoxazole for testing.
And (3) selecting and culturing the pure colonies for 18-24 hours, uniformly dissolving the pure colonies in 2-5 mL of sterile physiological saline, and adjusting the turbidity of the pure colonies to be equal to that of a 0.5 McLeod turbiditube. Antibiotics, bacterial liquid and TSB liquid culture medium are added into a 96-hole culture plate for overnight culture by using a test tube double dilution method, and liquid medicine groups with different concentrations are all three in parallel, so that the reliability of experimental data is ensured. And (3) measuring the minimum inhibitory concentration of the hemorrhizine on the streptococcus pneumoniae by using a microplate reader. The bacteriostatic result is judged according to the national standard administration committee of the united states clinical laboratory (CLSl2017), the judgment standard is shown in table 1, and the experimental result is shown in table 2. From this, it was found that the 2# strain had high resistance (type 2 for the 1# strain and type 6 for the 2# strain).
TABLE 1 results of the national Committee for standardization management of the clinical laboratory (CLSl2017) standards
TABLE 2 MIC results of drug sensitivity test of human Streptococcus pneumoniae
2. Inhibition effect of chelerythrine on multiple drug-resistant strains
In order to fully consider the medication safety, the single active ingredient chelerythrine is taken as a research object, and a standard strain (ATCC-49619, sensitive to antibiotics such as amoxicillin, meropenem, ertapenem, levofloxacin, ofloxacin, moxifloxacin and erythromycin) is taken as a reference for researching the drug resistance inhibition effect. Selecting and culturing the pure bacterial colonies for 18-24 h, uniformly dissolving the pure bacterial colonies in 2-5 mL of TSB liquid culture medium, adjusting the turbidity of the TSB liquid culture medium to be equal to that of a 0.5 McLeod turbiditube, and measuring the OD of the TSB liquid culture medium by using an enzyme-labeling instrument600The value is obtained. Preparing chelerythrine with concentration of 1000 μ g/mL with dimethyl sulfoxide as medicinal liquid, adding the medicinal liquid, bacterial liquid and TSB liquid culture medium into 96-well culture plate by test tube double dilution methodAnd (5) performing overnight culture, wherein three liquid medicine groups with different concentrations are parallel, so that the reliability of experimental data is ensured.
The Minimum Inhibitory Concentration (MIC) of chelerythrine against Streptococcus pneumoniae was determined using a microplate reader. And adding a drug dilution gradient to the cultured bacterial liquid by taking the MIC concentration as a reference, transferring the corresponding culture liquid to a sterile TSA solid culture medium for culturing for 24 hours, and if no single colony is generated, determining the corresponding concentration as the Minimum Bactericidal Concentration (MBC) of chelerythrine to streptococcus pneumoniae, wherein the experimental result is shown in Table 3.
TABLE 3 results of chelerythrine inhibition of Streptococcus pneumoniae
As shown in Table 3, chelerythrine has a good inhibitory effect on Streptococcus pneumoniae resistant to erythromycin, tetracycline and sulfamethoxazole, the MIC of the chelerythrine is 15.6 mug/mL, and the MBC of the chelerythrine is 31.2 mug/mL. The results show that chelerythrine has an inhibitory effect not only on the reference streptococcus pneumoniae strain, but also on streptococcus pneumoniae strains of the present invention (e.g., strain # 2).
According to the experimental results, by combining the characteristics of wide sources of Chinese herbal medicines, less adverse reactions, difficult generation of drug resistance and the like, the active single-product ingredient chelerythrine can be obtained to directly play an inhibiting role for clinically main streptococcus pneumoniae, so that the infection problem of the streptococcus pneumoniae can be effectively relieved or solved, the fatality rate is reduced, a scientific basis is provided for researching clinically separated bacteriostatic agents of the streptococcus pneumoniae, and a new thought and source is provided for developing drugs and antibiotic substitutes for inhibiting the streptococcus pneumoniae.
Claims (10)
1. Use of chelerythrine for inhibiting growth of Streptococcus pneumoniae is provided.
2. Use according to claim 1, characterized in that: the streptococcus pneumoniae is human streptococcus pneumoniae.
3. Use according to claim 1, characterized in that: the resistance of the streptococcus pneumoniae was determined by the microdilution method.
4. Use according to claim 1, characterized in that: the antibiotic which is tolerated by the streptococcus pneumoniae is selected from a plurality of erythromycin, tetracycline and compound sulfamethoxazole.
5. Use according to claim 1, characterized in that: the streptococcus pneumoniae is selected from erythromycin resistance, tetracycline resistance and compound sulfamethoxazole resistance streptococcus pneumoniae.
6. Use according to claim 5, characterized in that: the minimum bactericidal concentration of chelerythrine to streptococcus pneumoniae is 31.2 mug/mL, and the minimum bacteriostatic concentration is 15.6 mug/mL.
7. Use according to claim 1, characterized in that: the chelerythrine has in vitro killing effect on streptococcus pneumoniae and can inhibit in vitro growth of streptococcus pneumoniae.
8. Application of chelerythrine in preparing medicines for resisting streptococcus pneumoniae is provided.
9. Use according to claim 8, characterized in that: the streptococcus pneumoniae is human streptococcus pneumoniae.
10. Use according to claim 8, characterized in that: the streptococcus pneumoniae is selected from streptococcus pneumoniae resistant to various antibiotics in erythromycin, tetracycline and compound sulfamethoxazole.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010139842.0A CN111202735A (en) | 2020-03-03 | 2020-03-03 | Application of chelerythrine in inhibiting growth of streptococcus pneumoniae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010139842.0A CN111202735A (en) | 2020-03-03 | 2020-03-03 | Application of chelerythrine in inhibiting growth of streptococcus pneumoniae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111202735A true CN111202735A (en) | 2020-05-29 |
Family
ID=70783353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010139842.0A Pending CN111202735A (en) | 2020-03-03 | 2020-03-03 | Application of chelerythrine in inhibiting growth of streptococcus pneumoniae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111202735A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347512A (en) * | 2008-09-05 | 2009-01-21 | 郑州后羿制药有限公司 | Macleaya cordata injection and preparation thereof |
| CN102633805A (en) * | 2012-04-06 | 2012-08-15 | 西北农林科技大学 | Chelerythrine alcoholate, preparation method thereof and application in plant fungicide medicaments |
-
2020
- 2020-03-03 CN CN202010139842.0A patent/CN111202735A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347512A (en) * | 2008-09-05 | 2009-01-21 | 郑州后羿制药有限公司 | Macleaya cordata injection and preparation thereof |
| CN102633805A (en) * | 2012-04-06 | 2012-08-15 | 西北农林科技大学 | Chelerythrine alcoholate, preparation method thereof and application in plant fungicide medicaments |
Non-Patent Citations (7)
| Title |
|---|
| FANG MIAO等: "Structural modification of sanguinarine and chelerythrine and their antibacterial activity", 《NATURAL PRODUCT RESEARCH》 * |
| FANYAN MENG等: "Antifungal activity of the benzo[c]phenanthridine alkaloids from Chelidonium majus Linn against resistant clinical yeast isolates", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
| NAN HE等: "Antibacterial mechanism of chelerythrine isolated from root of Toddalia asiatica (Linn) Lam", 《BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE》 * |
| 周天达: "白屈菜红碱六种盐的制备及其刺激性实验", 《中药通报》 * |
| 张艳、杜方麓: "血水草的研究进展", 《时珍国医国药》 * |
| 梅长林主编: "《中国内科年鉴 2014》", 31 October 2015, 第二军医大学出版社 * |
| 王桂琴、强华主编: "《医学微生物学》", 30 September 2016, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2826473B1 (en) | Antibacterial use of patchoulol | |
| Urbina et al. | Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections | |
| Drago et al. | Comparative evaluation of synergy of combinations of β-lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniae | |
| CN110652512B (en) | Application of crizotinib in preparation of anti-gram-positive-bacteria drugs | |
| Kiani | Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections | |
| Flamm et al. | Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011) | |
| CN101543499B (en) | Application of natural compound ursolic acid on antibiosis | |
| CN103146802B (en) | Method for screening traditional Chinese medicines influencing drug resistance of escherichia coil generating ESBLs (extended spectyum beta lactamase) | |
| Hohl et al. | In vitro susceptibility of 33 clinical case isolates of Xanthomonas maltophilia: inconsistent correlation of agar dilution and of disk diffusion test results | |
| CN107812011B (en) | Antifungal pharmaceutical composition | |
| CN111202735A (en) | Application of chelerythrine in inhibiting growth of streptococcus pneumoniae | |
| CN110934859B (en) | Application of luteolin in inhibition of growth of multidrug-resistant providencia rettgeri | |
| CN110960545A (en) | Application of punicalagin in inhibiting growth of multidrug-resistant klebsiella pneumoniae | |
| Chartrand et al. | Moxalactam therapy of Haemophilus influenzae type b meningitis in children | |
| CN110772518A (en) | Application of sanguinarine in inhibiting growth of staphylococcus lugdunensis | |
| CN110934871B (en) | Application of sanguinarine in inhibiting growth of multiple drug-resistant serratia marcescens | |
| CN105998029A (en) | Antibacterial composite drug of levofloxacin hydrochloride for injection | |
| CN105853449A (en) | Combined antibacterial drug of amikacin sulfate for injection | |
| CN108042532B (en) | Antifungal pharmaceutical composition | |
| CN110934870A (en) | Application of sanguinarine in inhibition of growth of multidrug-resistant providencia rettgeri | |
| CN111166749A (en) | Application of sanguinarine in inhibiting growth of streptococcus pneumoniae | |
| CN111228280B (en) | Application of pulsatilla saponin A3 in inhibition of growth of multidrug-resistant providencia rettgeri | |
| Barry et al. | Resistance to ten different fluoroquinolone antibiotics following in vitro exposures to nalidixic acid | |
| CN111084836B (en) | Application of combination of thermionic acid and antibiotics in intervention of antibacterial action against pathogenic bacteria | |
| CN111000845B (en) | Application of chelerythrine in inhibition of growth of multidrug-resistant providencia rettgeri |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200529 |